Morgan Stanley Third Annual Global Healthcare Unplugged Conference
May 4 - 6, 2005

IMPORTANT US REGULATORY DISCLOSURES ON COVERED COMPANIES

The following analyst, strategist, or research associate (or a household member) owns securities in a company that he or she covers or recommends: Nancy Yu - Pfizer Inc (common stock), Merck & Co. (common stock); Jami Rubin - GlaxoSmithKline (common stock), Pfizer Inc (common stock). Morgan Stanley policy prohibits research analysts, strategists and research associates from investing in securities in their sub industry as defined by the Global Industry Classification Standard ("GICS," which was developed by and is the exclusive property of MSCI and S&P). Analysts may nevertheless own such securities to the extent acquired under a prior policy or in a merger, fund distribution or other involuntary acquisition.


Within the last 12 months, Morgan Stanley managed or co-managed a public offering of securities of Amylin Pharmaceuticals, Henry Schein, Inc., Barrier Therapeutics, Cubist Pharmaceuticals, Idenix Pharmaceuticals, Inspire Pharmaceuticals, Inc., AtheroGenics, Eyetech Pharmaceuticals, ImClone Systems, Advanced Medical Optics, Bausch & Lomb Inc., Chiron Corporation, Merck & Co., Amgen, Epigenomics, Pharmion, Vicuron, Triad, OSI Pharmaceuticals, Sepracor, Pfizer Inc.


Within the last 12 months, Morgan Stanley has received compensation for products and services other than investment banking services from GlaxoSmithKline Pharma, Humana Inc., Johnson & Johnson, Abbott...
Laboratories, Eli Lilly, Forest Labs, Biomet, Merck & Co., Amgen, GlaxoSmithKline, Aetna, Roche, Pfizer Inc.


Within the last 12 months, Morgan Stanley has either provided or is providing non-investment banking, securities-related services to and/or in the past has entered into an agreement to provide services or has a client relationship with the following companies covered in this report: GlaxoSmithKline Pharma, HCA, Inc., Becton Dickinson, Boston Scientific, Genentech, deCODE genetics, CYTYC Corporation, Advanced Medical Optics, MedImmune, Bausch & Lomb Inc., Chiron Corporation, Humana Inc., Johnson & Johnson, Abbott Laboratories, Eli Lilly, Forest Labs, Biomet, Merck & Co., Amgen, GlaxoSmithKline, Aetna, Actelion, Epigenomics, Roche, Qiagen NV, Serono, Stryker Corporation, Wilson Greatbatch, Zimmer Holdings, Inc., QLT Inc., Smith & Nephew, Pharmion, Vicuron, St. Jude Medical, Patterson Companies, Regeneron, Vertex Pharmaceuticals, Triad, The Medicines Company, OSI Pharmaceuticals, Shire Pharma Group, WellPoint, Inc., Renal Care Group Inc., PacifiCare Health Systems, Sepracor, Pfizer Inc.

The research analysts, strategists, or research associates principally responsible for the preparation of this research report have received compensation based upon various factors, including quality of research, investor client feedback, stock picking, competitive factors, firm revenues and overall investment banking revenues.


Morgan Stanley & Co. International Ltd. is a corporate broker to Shire Pharma Group.